Hancock Jaffe Laboratories, Inc. Stock

$3.99

1.01%

Nasdaq, Jul 03, 10:04 pm CET

ISIN

US41015N1063

Symbol

NVNO

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

Hancock Jaffe Laboratories, Inc. Stock price

$3.99

-6.47 61.86% 5Y

Nasdaq, Closing price Thu, Jul 03 2025

+0.04 1.01%

ISIN

US41015N1063

Symbol

NVNO

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Key metrics

Basic

Market capitalization

$70.0m

Enterprise Value

$31.0m

Net debt

positive

Cash

$38.9m

Shares outstanding

18.0m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

negative

P/B

1.9

Financial Health

Equity Ratio

93.3%

Return on Equity

-52.4%

ROCE

-59.2%

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

$-23.2m | -

EBIT

$-23.3m | $-25.9m

Net Income

$-21.3m | $-19.8m

Free Cash Flow

$-17.5m

EPS

$-1.1

FCF per Share

$-1.0

Short interest

2.5%

Employees

Rev per Employee

$0.0

As a Free StocksGuide user, you can view scores for all 6,966 stocks worldwide.

Get Started for Free Today

Hancock Jaffe Laboratories, Inc. Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a Hancock Jaffe Laboratories, Inc. forecast:

6x Buy

86%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a Hancock Jaffe Laboratories, Inc. forecast:

Buy

86%

Hold

14%

Analyst Estimates with Stock Price Targets

Financial data from Hancock Jaffe Laboratories, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	11 11	6% 6% -
- Research and Development Expense	12 12	10% 10% -
EBITDA	-23 -23	3% 3% -
- Depreciation and Amortization	0.10 0.10	0% 0% -
EBIT (Operating Income) EBIT	-23 -23	3% 3% -
Net Profit	-21 -21	4% 4% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Hancock Jaffe Laboratories, Inc. Stock News

Neutral

Accesswire

●

30 days ago

Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting

Interim two-year follow-up data from 42 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit at 24 months compared to baseline 83% of subjects maintained a clinically meaningful benefit with a 3 or more point improvement in Revised Venous Clinical Severity Score (rVCSS) 9.1 point average rVCSS improvement among the clinically meaningful benef...

Neutral

Accesswire

●

about 2 months ago

enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer

IRVINE, CA / ACCESS Newswire / May 19, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, announced the appointment of Jennifer Bright as Chief Financial Officer, effective today, May 19, 2025. Ms. Bright brings more than 25 years of financial and strategic leadership experience built a...

Neutral

Accesswire

●

about 2 months ago

Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery

Promising results from the first-in-human study demonstrated that, at three-years post implantation, VenoValve remained safe and effective--achieving a high rate of patency, restoring deep venous competence and maintaining clinical benefits Company has submitted PMA application for the VenoValve to the U.S. Food and Drug Administration (FDA) with a decision anticipated in the second half of 202...

More Hancock Jaffe Laboratories, Inc. News

Company Profile

Hancock Jaffe Laboratories, Inc. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. Its products include The Bioprosthetic Heart Valve, The CoreoGraft, and The Venous Valve. The company was founded by Norman Jaffe on December 22, 1999 and is headquartered in Irvine, CA.

Head office	United States
CEO	Robert Berman
Employees	37
Founded	1999
Website	envveno.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now